Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kareus Therapeutics S.A.
DescriptionCombination of a generally recognized as safe (GRAS) molecule combined with a marketed non-Alzheimer's disease product using Kareus' Karlect technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerQuintiles Transnational Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today